May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Efficacy of Infliximab Treatment in Behcet’s Disease With Refractory Uveoretinitis
Author Affiliations & Notes
  • Y. Yamada
    Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan
  • S. Sugita
    Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan
  • K. Kamoi
    Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan
  • Y. Iwanaga
    Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan
  • M. Yokota
    Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan
  • H. Tanaka
    Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan
  • H. Takase
    Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan
  • M. Mochizuki
    Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan
  • Footnotes
    Commercial Relationships  Y. Yamada, None; S. Sugita, None; K. Kamoi, None; Y. Iwanaga, None; M. Yokota, None; H. Tanaka, None; H. Takase, None; M. Mochizuki, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4723. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Yamada, S. Sugita, K. Kamoi, Y. Iwanaga, M. Yokota, H. Tanaka, H. Takase, M. Mochizuki; Efficacy of Infliximab Treatment in Behcet’s Disease With Refractory Uveoretinitis. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4723. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Behcet’s disease (BD) can cause sight-threatening uveoretinitis. Refractory uveitis in the disease is not well managed even with cyclosporine A (CsA) in many patients. In this study, we evaluated the efficacy and safety of a new therapy, infliximab (anti-TNFα antibody) on refractory uveitis in BD.

Methods: : Subjects were patients with BD at uveitis clinic of TMD Hospital between 1998 and 2007 treated with 3-5 mg/kg of CsA (n=41) or 5mg/kg of infliximab (n=11). Extra-ocular systemic symptoms as well as adverse events during the whole periods on each agent were compared between the two groups. Number of episodes of acute uveitis attacks and vision were compared between the two groups, but in limited periods of treatments, i.e. 6 months before each treatment and initial 6 months after the treatment (number of patients: 20 in CsA group and 9 in inflixmab group).

Results: : Uveitis attacks in 6 months before the treatment were 3.1±2.3 in infliximab group, while 3.3±2.4 in CsA group (n.s.), and in the 6 months after the initiation of the treatment were 0.1±0.3 in infliximab group, while 1.2±1.2 in CsA group (P<0.05). Infliximab improved or unchanged the vision in 89% of eyes, while 93% in CsA (n.s.). Complete disappearance of extra-ocular symptoms was achieved in 64% of infliximab-treated patients, while only in 2% of CsA-treated patients (P<0.001). Infliximab induced a few adverse events, e.g. skin eruption in 3 patients, leucopenia in 2 and infusion reaction in one patient, but no serious adverse events such as tuberculosis. CsA caused many adverse events: central nervous system symptoms in 10 patients, renal toxicity in 7 patients, and 6 of them discontinued CsA due to the side effects.

Conclusions: : The new therapy with infliximab is effective in refractory uveitis in patients with BD. Comparing to CsA, infliximab is much more effective and much less side effects.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×